Although bermekimab initially appeared to have potential as a novel and effective treatment for AD in one early phase 2 clinical trial, the more rigorously designed trial, the GENESIS phase 2b study, did not confirm those results, suggesting that blocking IL-1α with bermekimab does not provide a viable approach to AD monotherapy. Here, IL1A is linked to Alzheimer disease.